Regulation of the Skeletal Muscle Ryanodine Receptor/Ca\(^{2+}\)-release Channel RyR1 by S-Palmitoylation*

Received for publication, January 8, 2014, and in revised form, February 3, 2014. Published, JBC Papers in Press, February 7, 2014, DOI 10.1074/jbc.M114.548925

Ruchi Chaube†, Douglas T. Hess‡, Ya-Juan Wang§, Bradley Plummer†, Qi-An Sun‡, Kennneth Laurita§, and Jonathan S. Stamler†‡

From the †Institute for Transformative Molecular Medicine and Department of Medicine, Case Western Reserve University School of Medicine and University Hospitals, Cleveland, Ohio 44106, the ‡Center for Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, the ¶Heart and Vascular Research Center, MetroHealth Campus of Case Western Reserve University, Cleveland, Ohio 44109, and the ‡Harrington Discovery Institute, University Hospitals Case Medical Center, Cleveland, Ohio 44106

Background: Excitation-contraction coupling in striated muscle requires intracellular Ca\(^{2+}\) release through ryanodine receptor/Ca\(^{2+}\)-release channels (RyRs).

Results: S-Palmitoylation is a previously unidentified post-translational modification of skeletal muscle RyR1. Diminishing S-palmitoylation significantly diminishes RyR1 activity including stimulus-dependent Ca\(^{2+}\) release. S-Palmitoylation provides a previously unidentified mechanism to regulate Ca\(^{2+}\) release through RyR1.

Conclusion: S-Palmitoylation is likely to regulate Ca\(^{2+}\) flux in many cell types.

The ryanodine receptor/Ca\(^{2+}\)-release channels (RyRs) of skeletal and cardiac muscle are essential for Ca\(^{2+}\) release from the sarcoplasmic reticulum that mediates excitation-contraction coupling. It has been shown that RyR activity is regulated by dynamic post-translational modifications of Cys residues, in particular S-nitrosylation and S-oxidation. Here we show that the predominant form of RyR in skeletal muscle, RyR1, is subject to Cys-directed modification by S-palmitoylation. S-Palmitoylation targets 18 Cys within the N-terminal, cytoplasmic region of RyR1, which are clustered in multiple functional domains including those implicated in the activity-governing protein-protein interactions of RyR1 with the L-type Ca\(^{2+}\) channel Ca\(_{\text{v}}\)1.1, calmodulin, and the FK506-binding protein FKBP12, as well as in “hot spot” regions containing sites of mutations implicated in malignant hyperthermia and central core disease. Eight of these Cys have been identified previously as subject to physiological S-nitrosylation or S-oxidation. Diminishing S-palmitoylation directly suppresses RyR1 activity as well as stimulus-coupled Ca\(^{2+}\) release through RyR1. These findings demonstrate functional regulation of RyR1 by a previously unreported post-translational modification and indicate the potential for extensive Cys-based signaling cross-talk. In addition, we identify the sarco/endoplasmic reticular Ca\(^{2+}\)-ATPase 1A and the α\(_{15}\) subunit of the L-type Ca\(^{2+}\) channel Ca\(_{\text{v}}\)1.1 as S-palmitoylated proteins, indicating that S-palmitoylation may regulate all principal governors of Ca\(^{2+}\) flux in skeletal muscle that mediates excitation-contraction coupling.

Post-translational protein modifications, which provide the principal cellular mechanism for regulating protein function, target multiple amino acids. Cysteine (Cys) residues are distinctive targets in that they are acted on through multiple chemistries that mediate separate, reversible, and dynamic modifications including S-nitrosylation, S-oxidation, and S-palmitoylation. These modifications have been shown to operate on thousands of proteins and thereby to regulate a large array of signal transduction pathways. The ryanodine receptor/Ca\(^{2+}\)-release channels (RyR1–3) localized to the sarcoplasmic reticulum (SR) of skeletal and cardiac striated muscle as well as to the dendritic compartment of neurons, provide a laboratory for elucidating the regulation of and interplay between Cys-based post-translational modifications. RyRs are unusually large proteins (approximately 5000 amino acids) that contain approximately 100 Cys residues. RyR1, the predominant form in skeletal muscle, is S-nitrosylated under physiological conditions at a single Cys residue (Cys-3635) (1, 2). Physiological S-nitrosylation, which reflects production of nitric oxide by a nitric-oxide synthase localized to the sarcolemma, is coupled to muscle pO\(_2\) through O\(_2\)-dependent S-oxidation: at relatively high pO\(_2\) (ambient O\(_2\)), S-oxidation of a small set of thiols on average (~6), which does not include Cys-3635 (3), allosterically regulates S-nitrosylation of Cys-3635 (1) and enhances RyR1 activity (1, 4). This average set of thiols represents stoichiometric S-oxidation of a larger set of Cys residues that constitute an allosteric network, the constituents of which have been identified recently (5). pO\(_2\)-coupled S-oxidation is mediates by O\(_2\)-dependent production of H\(_2\)O\(_2\) by an SR-resident NADPH oxidase, Nox4 (4), and represents at least in part the formation of intra-RyR1 subunit disulfide linkages (5).

The abbreviations used are: RyR, ryanodine receptor/Ca\(^{2+}\)-release channel; acyl-RAC, resin-assisted capture of S-acetylated proteins; 2-BrP, 2-bromo-palmitate; LC-MS/MS, liquid chromatography and tandem mass spectrometry; MBB, monobromobimane; 17-ODYA, 17-octadecacylic acid; SERCA, sarco/endoplasmic reticular Ca\(^{2+}\)-ATPase; SR, sarcoplasmic reticulum; T-tubule, transverse tubule; TTBTA, Tris[1-benzyl-1H-1,2,3-triazol-4-yl] methyl]amine; TCEP, Tris[2-carboxyethyl]phosphine hydrochloride.

* This work was supported, in whole or in part, by National Institutes of Health Grants R01 HL099130 and R01 AR018687.
† To whom correspondence should be addressed: Institute for Transformative Molecular Medicine, Wolstein Research Bldg. 4129, 2103 Cornell Rd., Cleveland, OH 44106. Tel.: 216-368-5725; Fax: 216-368-2968; E-mail: jonathan.stamler@case.edu.
‡ Palmitoylation is a previously unidentified post-translational modification of skeletal muscle RyR1. Diminishing S-palmitoylation provides a previously unidentified mechanism to regulate Ca\(^{2+}\) release through RyR1.
We report here that RyR1 is modified by an additional form of Cys-directed post-translational modification, S-palmitoylation, the thioester-linked addition to a Cys thiol of a 16-carbon saturated fatty acid. Mass spectrometric analysis identified 18 S-palmitoylated RyR1 Cys residues, which are distributed widely within RyR1 in multiple functional domains. Removing palmitate from RyR1 significantly diminishes RyR1 activity both in situ (intact SR vesicles) and in vitro (purified RyR1), and moreover, in cultured myofibers, inhibiting palmitoylation significantly diminishes electrically evoked Ca\(^{2+}\) release through RyR1. Thus, RyR1 is subject to multisite, activity-governing S-palmitoylation.

**EXPERIMENTAL PROCEDURES**

**Preparation of SR Vesicles and Purification of RyR1**—SR vesicles were prepared from rabbit hind-limb muscle essentially as described (4, 6). In brief, tissue was homogenized in buffer containing 20 mM HEPES, pH 7.4, 2 mM EDTA, 0.2 mM EGTA, 0.3 M sucrose, and protease inhibitors (100 nM aprotinin, 20 \(\mu\)M leupeptin, 1 \(\mu\)M pepstatin, 0.2 M PMSE, 1 M benzamidine). Homogenates were centrifuged at 9200 \(\times\) g for 20 min, and the resultant supernatant was centrifuged at 100,000 \(\times\) g for 1 h. The resultant membrane-enriched microsomal pellet was resuspended and fractionated on a continuous 20–45% sucrose gradient by centrifugation at 100,000 \(\times\) g for 14 h. Fractions containing SR vesicles were eluted, and SR vesicles were collected by centrifugation at 120,000 \(\times\) g, resuspended, aliquoted, and stored under liquid nitrogen. Unless otherwise noted, the heavy SR fraction was used for subsequent analysis. RyR1 was purified from CHAPS-solubilized SR vesicles by sucrose density gradient centrifugation as described (4, 7). Protein concentrations were determined with a bicinchoninic acid-based assay.

**Acyl-RAC (Resin-assisted Capture of S-Acylated Proteins)—**The acyl-RAC method was applied essentially as described (8, 9) with minor modifications. SR vesicles were solubilized in thiol-blocking buffer (100 mM HEPES, 1.0 mM EDTA, 2.5% SDS, 50 mM N-ethylmaleimide, pH 7.5) at a final protein concentration of 1 mg/ml and incubated at 50 °C for 1 h with frequent vortexing. Following acetylation precipitation, the pellet was rinsed four times with 70% acetone, repelleted, and rinsed four times with 1 ml of 50 mM NH\(_4\)HCO\(_3\), 1 mM EDTA, 1 mM NH\(_2\)OH (pH adjusted to 7.0 with NaOH) was added followed by 40 \(\mu\)l of prewashed thiopropyl-Sepharose (Amersham Biosciences). Binding was carried out on a rotator at room temperature for 4 h. Resins were pelleted at 1000 \(\times\) g following each of 3–5 washes with binding buffer and either eluted in 40 \(\mu\)l of Laemmli loading buffer (2.1% SDS, 66 mM Tris, 26% glycerol w/v, 50 mM DTT) at 42 °C for 10 min for Western blotting or silver staining, or processed for mass spectrometric analysis. Western blotting for RyR1, SERCA 1A, and the \(\alpha\) subunit of Ca\(_{\text{v}1.1}\) employed, respectively, mouse monoclonal antibodies 34C, VE121Gp, and 1A (Pierce).

**Liquid Chromatography and Tandem Mass Spectrometry (LC-MS/MS)—** Following acyl-RAC, thiopropyl-Sepharose was suspended in 1 ml of 50 mM NH\(_4\)HCO\(_3\), 1 mM EDTA, 1 mM CaCl\(_2\) containing 0.5 \(\mu\)g of trypsin (Promega) and rotated at 37 °C for 12 h. Following five washes with 1 ml of wash buffer containing 500 mM NaCl, 1% Nonidet P-40 and five washes with 1 ml of 50 mM NH\(_4\)HCO\(_3\), the resin was resuspended in 50 \(\mu\)l of 5 mM TCEP in 50 mM NH\(_4\)HCO\(_3\), pH 8.0, and heated at 60 °C for 30 min with frequent vortexing. The resin was then pelleted by centrifugation at 2000 \(\times\) g for 2 min, the eluate was removed, and eluted peptides were labeled with 15 mM iodoacetamide in 50 mM NH\(_4\)HCO\(_3\) for 45 min at room temperature in the dark. Peptides were dried under reduced pressure and resuspended in 0.5% trifluoroacetic acid, 5% acetonitrile. Residual iodoacetamide and TCEP were removed with a C18 spin column (Pierce) according to the manufacturer’s instructions, made 0.1% with respect to formic acid, and analyzed by LC-MS/MS. Peptides were separated via capillary liquid chromatography with a Waters nanoAquity system (Waters Corp., Milford, MA). The mobile phase A (aqueous) contained 0.1% formic acid in 5% acetonitrile, and mobile phase B (organic) contained 0.1% formic acid in 85% acetonitrile. Separation was achieved using a C18 column (BEH300, 75 \(\mu\)m \(\times\) 20 cm; Waters Corp.) and a 180-min gradient of 6–45% mobile phase B at a flow rate of 300 nl/min. Mass spectrometric analysis was performed using a hybrid linear ion trap Orbitrap Velos mass spectrometer (LTQ-Orbitrap Velos; Thermo, Waltham, MA). A survey scan was carried out at 60,000 resolution, followed by 10 data-dependent collision-induced dissociation fragmentations. Peptide identification was achieved by searching against the rabbit RyR1 protein sequence (access no. P11716.1) or the nonredundant rabbit database from the National Centre for Biotechnology Information (NCBI, 2011). Protein identification using Sequest (10) or ProLuCID (11), and DTASelect (12, 13) was carried out with the Integrated Proteomics Pipeline (IP2; Integrated Proteomics Applications, San Diego) or MassMatrix (14). Mass accuracy was limited to 10 ppm for precursor ions and 0.6 Da for product ions, with tryptic enzyme specificity and up to two missed cleavages. Variable modifications included cysteine alkylation by iodoacetamide (57 Da) or N-ethylmaleimide (125 Da), and methionine oxidation (16 Da). Identified spectra were checked manually to ensure quality.

**Assay of RyR1 Activity by \(^{[3H]}\)Ryanodine Binding—**RyR1 activity was assayed by \(^{[3H]}\)ryanodine binding essentially as described (4, 15). SR vesicles derived from rabbit hind-limb muscle were incubated for 2 h at room temperature in 100 mM HEPES, pH 7, 1 mM EDTA with or without 0.5 mM NH\(_4\)OH (pH 7.0 by titration with NaOH), and collected by centrifugation at 100,000 \(\times\) g for 1 h at 4 °C. The pellets were washed three times with 100 mM phosphate buffer, pH 7.4, and resuspended in \(^{[3H]}\)ryanodine binding buffer comprising 20 mM imidazole, 125 mM KCl, pH 7.0, 1 mM CaCl\(_2\), 0.3 mM Pefabloc (Roche Applied Science), and 30 \(\mu\)M leupeptin and containing 5 mM \(^{[3H]}\)ryanodine (PerkinElmer Life Sciences). Nonspecific binding was determined by co-incubation with a 1000-fold excess of unlabeled ryanodine. After incubation overnight at room temperature, samples were diluted with 20 volumes of H\(_2\)O at 4 °C and distributed evenly on Whatman GF/B filters soaked with 2% (w/w) polyethyleneimine. Filters were washed three times under vacuum with 5 ml of buffer/wash (1 mM Pipes, 0.1 M KCl, pH 7.0), and the radioactivity remaining on the filters was...
measured by liquid scintillation counting. We also employed \[^{3}H\]ryanodine binding to assay the activity of RyR1 purified from CHAPS-solubilized SR vesicles by sucrose density gradient centrifugation, as above. Fractions containing RyR1 were pooled, and 35 \(\mu\)g of protein was added to 1 ml of \[^{3}H\]ryanodine binding buffer and incubated overnight at room temperature. Binding was terminated by the addition of a 10-fold excess of cold water, and the resultant solution was spotted on filters and processed as above.

**Assay of Intracellular Ca\(^{2+}\) Release in Primary Myocytes**—Single muscle fibers were isolated from mouse (C57BL/6) flexor digitorum brevis muscle as described (4, 16). In particular, muscle fiber bundles were separated by blunt dissection and incubated in Tyrode’s solution containing 2 mg/ml collagenase (type II; Worthington) for 2 h at 37 °C with gentle agitation and then transferred to DMEM supplemented with BSA (0.2% w/v), 50 units/ml penicillin, and 50 mg/ml streptomycin. Individual myofibers were generated by titration, collected by centrifugation at 1000 \(\times\) \(g\) for 1 min, and resuspended in DMEM. Myofibers were plated and incubated overnight in DMEM (37 °C; 5% CO\(_2\)/95% O\(_2\)) with or without 2-bromo-palmitate (2-BP, 1 \(\mu\)M) for 45 min, collected by centrifugation at 1000 \(\times\) \(g\) for 1 min, and resuspended in Tyrode’s solution. Myofibers were then placed in a sealed chamber designed for field stimulation (Warner Instruments) that was superfused with a continuous flow of Tyrode’s solution externally sparged with room air and visualized using an inverted Axiovert microscope (Zeiss). Ca\(^{2+}\) transients were evoked by electrical stimulation at 1 Hz (50-ms square-wave pulse, 40–50 V). Evoked Ca\(^{2+}\) transients were recorded with a CCD camera system (PentaMAX; Princeton Instruments), and the amplitudes of transients were calculated as the difference between peak and baseline levels normalized with respect to baseline fluorescence (\(F/F_0\)).

**Assay of RyR1 Free Thiol Content**—The thiol-specific fluorescent agent monobromobimane (MBB; Molecular Probes) (17) was used to determine the free thiol content of RyR1 derived from control versus NH\(_2\)OH-treated SR vesicles. SR vesicles were prepared as above, and 3 mg total vesicle protein was incubated for 4 h in 100 mM HEPES, pH 7, 1 mM EDTA, 50 \(\mu\)M MBB, with or without 500 mM NH\(_2\)OH. Vesicles were then collected by centrifugation at 100,000 \(\times\) \(g\) and solubilized in CHAPS prior to isolation of RyR1 by sucrose density gradient centrifugation, as above. This fraction was then subjected to SDS-PAGE, the resultant gel was silver-stained, and the band containing RyR1 (verified by Western blotting) was excised.

Identification of RyR1 was on the basis of Western blotting of lysates run in parallel, and quantification of results was carried out by normalizing with respect to sample content of RyR1.

**RESULTS**

**RyR1 Is Modified by S-Palmitoylation**—We employed the acyl-RAC method (which we developed (8)) to probe for S-palmitoylated proteins in SR vesicles, a subcellular fraction highly enriched for SR that also contains some transverse tubule (T-tubule) membrane (4). In this method (8, 9), free thiols are blocked, treatment with neutral hydroxylamine selectively cleaves thioester-linked palmitate from modified Cys, and proteins are coupled to thiopropyl-Sepharose resin through the free thiols created by hydroxylamine treatment. Subsequently eluted proteins may be analyzed intact, or peptides may be eluted following proteolytic digestion for mass spectrometric identification of specific palmitate-modified Cys.

A number of proteins were pulled down by acyl-RAC from solubilized SR vesicles in a hydroxylamine-dependent fashion, as revealed by silver staining following SDS-PAGE of resin elu-
ates (Fig. 1A). The most prominent substrates were identified as RyR1, the sarco/endoplasmic reticulum Ca\(^{2+}\) -ATPase SERCA 1A (ATP2A1) and the \(\alpha_{1S}\) subunit of Cav1.1 (L-type Ca\(^{2+}\) channel, dihydropyridine receptor (DHPR)) on the basis of their characteristic position (M\(_2\)) and by Western blotting (Fig. 1, A and B). LC-MS/MS of peptides eluted from the immobilizing resin following trypsin digest confirmed the identification of RyR1 and SERCA 1A (Figs. 1C, 1F, and Table 1). We did not identify peptides from the \(\alpha_{1S}\) subunit of Cav1.1 by LC-MS/MS under the conditions employed. To further control for possible false-positive mass spectrometric identification of palmitoylated Cys residues, eluates from resin incubated with solubilized SR vesicles that had not been treated with hydroxylamine were analyzed in parallel by LC-MS/MS in every experiment, and Cys-containing peptides were never identified in the absence of hydroxylamine.

**Identification of S-Palmitoylated Cys Residues—Acyl-RAC coupled to LC-MS/MS identified 18 palmitoylated Cys residues within RyR1 (seen in at least three of five separate experiments) (Fig. 2 and Table 1). This represents a minimum number of palmitoylated Cys residues because theoretical analysis indicates that trypsin digest provides coverage by LC-MS/MS of no more than 76% of Cys residues within RyR1 (i.e. 76 of 100 Cys residues found in one or more peptides of ~800–3000 Da). Palmitoylated Cys residues were distributed throughout the N-terminal cytoplasmic domain of RyR1, but appeared to be grouped in three principal clusters (Fig. 2). The most N-terminal cluster comprised 6 of 18 Cys residues between and including RyR1 residues 24–537, which were localized to functional domains previously identified as mediating the interaction of RyR1 with FK506-binding protein 12 (FKBP12) and as “hot spot” domains implicated in malignant hyperthermia and central core disease. A second cluster comprised 6 of 9 Cys residues between and including RyR1 residues 2237–2565, which were localized to functional domains previously identified as participating in the interaction of RyR1 with Cav1.1 and to hot spot domains for malignant hyperthermia and central core disease. The third cluster comprised 4 of 4 Cys residues between and including RyR1 residues 3170–3635, which were localized to a Cav1.1-interacting domain as well as the domain implicated in the interaction of RyR1 with calmodulin. All palmitoylated Cys residues identified in rabbit RyR1 are conserved in mammalian RyR1s, including human RyR1, with the exception of Cys-305. In addition, 12 of 18 and 14 of 18 palmitoylated Cys residues identified in RyR1 are conserved in RyR2 and RyR3, respectively (Table 1). Notably, 7 of 18 palmitoylated Cys residues have been identified previously as subject to physiological oxygen-coupled S-oxidation (5), including 5 of 6 Cys within the N-terminal cluster of palmitoylated Cys residues (Fig. 2). The principal site of physiological S-nitrosylation (Cys-3635) (2) was also identified as a site of S-palmitoylation (Figs. 1C and 2).

In addition, mass spectrometric analysis identified 8 palmitoylated Cys (seen in at least two of four separate experiments) located throughout the cytoplasmic domain of SERCA 1A (Cys-12, Cys-344, Cys-349, Cys-364, Cys-471, Cys-636, Cys-674, and Cys-675); trypsin digest coupled with LC-MS/MS as employed would in theory yield coverage of 18 of 24 Cys residues within SERCA 1A. Six of the 8 Cys residues identified as palmitoylated in SERCA 1A (ATP2A1) are conserved in SERCA 2 (ATP2A2) and SERCA 3 (ATP2A3); the exceptions are Cys-12 and Cys-674. Thus, the principal proteins that govern SR Ca\(^{2+}\) flux are subject to S-palmitoylation, and there exists the potential for extensive cross-talk between S-palmitoylation and alternative Cys-based post-translational modifications of RyR1.

**Functional Effects of Diminished S-Palmitoylation**—To assess a possible role for S-palmitoylation in regulation of RyR1 activity, we compared the activity of RyR1 in native SR vesicles with the activity in vesicles treated with neutral hydroxylamine.
to remove thioester-linked palmitate. Treatment of SR vesicles with hydroxylamine (0.5 mM, 2 h) reduced RyR1 activity by ~62% as assessed by assay of \(^{3}H\)-ryanodine binding (Fig. 3A). Ryano-
dine binds to RyR1 in the active state in which the Ca\(^{2+}\) pore is open, and the \(^{3}H\)-ryanodine binding assay therefore provides a direct indication of channel open probability (\(p_o\)). To verify that treatment with hydroxylamine depalmitoylated RyR1, we further purified RyR1 from CHAPS-solubilized untreated and hydroxylamine-treated SR vesicles in which free thiols had been labeled with the fluorescent thiol reporter MBB, employing density gradient centrifugation followed by SDS-PAGE of RyR1-enriched gradient fractions to complete the purification. The band corresponding to RyR1 was excised and subjected to

tryptin digest followed by assay of MBB fluorescence. The average hydroxylamine-treated to untreated ratio of MBB fluorescence was 1.45 (±0.22 S.D.) (Fig. 3B). We (4) and others (21) have previously reported that RyR1 possesses an average of approximately 35 free thiols/RyR1 monomer under similar conditions (room air) as assessed by MBB assay. Thus, the 45% increase in MBB fluorescence following hydroxylamine treatment (measured within the linear range of the MBB assay) represents a gain of 16 thiols/RyR1 monomer on average, consis-

TABLE 1

|             | RyR1 | RyR2 | RyR3 |
|-------------|------|------|------|
| 24          | X    | X    |      |
| 36          |      |      |      |
| 120         |      |      |      |
| 253         |      |      |      |
| 305         |      |      |      |
| 537         |      |      |      |
| 1040        | X    | X    |      |
| 1674        |      |      |      |
| 2021        | X    | X    |      |
| 2237        | X    |      |      |
| 2326        |      |      |      |
| 2363        | X    |      |      |
| 2555        |      |      |      |
| 2565        |      |      |      |
| 3170        |      |      |      |
| 3193        |      |      |      |
| 3170        |      |      |      |
| 3402        |      |      |      |
| 3635        |      |      |      |

FIGURE 2. Localization of S-palmitoylated Cys within rabbit RyR1 (shown in red), as identified by acyl-RAC. Previously identified sites of physiological S-oxidation (S-Ox) (5) and S-nitrosylation (S-NO) (2) are indicated. Transmembrane domains, regions implicated in the interaction of RyR1 with the L-type Ca\(^{2+}\) channel Ca\(_{1,1}\) (dihydropyridine receptor, DHPR), FK506-binding protein 12 (FKB12), and calmodulin (CaM), leucine/isoleucine zipper (LIZ) motifs, and the SPRY1 domain, as well as hot spot regions implicated in malignant hypothermia/central core disease (MH, CCD), are delineated on the basis of the human RyR1 sequence (reviewed recently in Ref. 39).

FIGURE 3. Suppression of RyR1 activity by depalmitoylation with hydroxyl-
amine (NH\(_{2}\)OH). A, at left, depalmitoylation by treatment with hydroxyla-
mine diminishes RyR1 activity in SR vesicles as assessed by \(^{3}H\)-ryanodine binding (\(n = 3\) separate experiments; *, \(p < 0.05\)). At right, hydroxylamine treatment diminishes the activity of RyR1 purified from untreated SR vesicles versus SR vesicles treated with hydroxylamine prior to assay (\(n = 4\) separate experiments; *, \(p < 0.05\)). B, assay of free thiols by MBB fluorescence in RyR1 purified from untreated or hydroxylamine-treated SR vesicles demonstrates hydroxylamine-dependent generation of free thiols, indicative of depalmito-
ylation (\(n = 4\) separate experiments; *, \(p < 0.05\)). In A and B, error bars indicate S.E.
tent with our identification of 18 Cys residues within RyR1 that are subject to S-palmitoylation. Our analysis does not allow us to deduce the stoichiometry of S-palmitoylation of individual Cys residues, and it should be noted that the magnitude of the increase in free thiols following treatment with hydroxylamine will reflect the fact that, as noted above, 7 of the Cys we identified as S-palmitoylated were identified previously as subject to (hydroxylamine-insensitive) substoichiometric S-oxidation under similar conditions (5) and that an additional palmitoylated Cys residue (Cys-3635) is subject to activity- and pO2-dependent S-nitrosylation (2) (we detect S-nitrosylation of RyR1 in SR vesicles under basal conditions by SNO-RAC (Ref. 8 and data not shown). In addition, we assayed RyR1 activity by [3H]ryanodine binding after further purification of RyR1 from untreated and hydroxylamine-treated SR vesicles by the well established method of density gradient centrifugation following CHAPS solubilization. Hydroxylamine treatment decreased the activity of RyR1 in RyR1-enriched gradient fractions by ~72% (Fig. 3A), which is closely comparable with the decrease observed in intact SR vesicles. These findings are consistent with the conclusion that depalmitoylation of RyR1 suppresses RyR1 activity at least in part through a direct effect on channel configuration.

We next examined in cultured myofibers (derived from the flexor digitorum brevis muscle of mice) the effects of inhibiting S-palmitoylation with 2-BP on stimulus-coupled intracellular Ca2+ release through RyR1, induced by electrical depolarization (pacing at 1 Hz) and assayed by Fluo 3-AM fluorescence. If palmitate turns over on one or more Cys residues within RyR1 (and/or other SR proteins) under basal conditions, then incubation with 2-BP, which would prevent palmitoylation, would result in a time-dependent decrease in palmitoylation state that would reach a plateau after an interval determined by the half-life of palmitate turnover. We found that incubation of myofibers with 2-BP (1 μM) prior to assessment of intracellular Ca2+ release decreased the magnitude of release by ~44% and that the suppressive effect of 2-BP increased with increasing incubation interval and plateaued within 2 h (Fig. 4A and B). Metabolic labeling (2 h) with the ω-alkynyl-palmitate analog 17-ODYA followed by bio-orthogonal click chemistry with biotin-azide (18–20) demonstrated directly turnover of palmitate on RyR1 under basal conditions, which was greatly diminished by co-incubation with 2-BP (1 μM) (Fig. 4C). Finally, we verified that, as reported previously (4), depolarization-induced Ca2+ release in cultured myofibers as assessed by Fluo 3-AM fluorescence was largely dependent upon RyR1 because it was rapidly eliminated by incubation with ryanodine, to selectively inhibit RyR1 (Fig. 4D). Thus, our results indicate that depalmitoylation, likely of RyR1, substantially diminishes stimulus-coupled Ca2+ release through RyR1.

**DISCUSSION**

The continuously expanding list of mammalian proteins shown to be modified by S-palmitoylation now exceeds several hundred substrates. Although the nicotinic cholinergic receptor localized to the skeletal muscle sarcolemma was identified early on as a substrate for S-palmitoylation (22), S-palmitoylation of skeletal muscle membrane proteins localized to internal, SR, and T-tubule membranes has not been reported previously. Our identification of RyR1, SERCA 1A (localized to the SR), and the α1S subunit of CaV1.1 (localized to T-tubules) as substrates for S-palmitoylation indicates that S-palmitoylation modifies the principal governors of Ca2+ release that mediate excitation-contraction coupling in skeletal muscle.

RyR1, SERCA 1A, and the α1S subunit of CaV1.1 are all previously unidentified substrates of S-palmitoylation. RyR1 rep-
S-Palmitoylation of Skeletal Muscle RyR1

resresents the first example of S-palmitoylation of an intracellular Ca\(^{2+}\) release channel; the \(\alpha_{1S}\) subunit of Ca\(_V\)1.1, the prototypical voltage-gated Ca\(^{2+}\) channel, represents the first example of S-palmitoylation of a pore-forming \(\alpha\)-subunit of Ca\(_V\) channels; SERCA 1A, the prototype of the family of ion-transporting P-type ATPases, represents the first verified example of S-palmitoylation of a member of the Ca\(^{2+}\)-ATPase subfamily (although large scale proteomic screening has identified ATP2A2 and ATP2A3 as candidate S-palmitoylated substrates (23)). It may be anticipated that S-palmitoylation of additional isoforms of RyR\(_\alpha\), Ca\(_V\) \(\alpha\)-subunits, and SERCA will regulate Ca\(^{2+}\) flux in multiple cell types in addition to skeletal muscle.

We identified 18 sites of S-palmitoylation within RyR1, which are clustered in multiple functional domains including those implicated in the activity-governing protein–protein interactions of RyR1 with Ca\(_V\), camodulin, and FKB12, as well as in hot spot regions containing sites of mutations implicated in malignant hyperthermia and central core disease. There is precedent for multisite S-palmitoylation of both voltage- and ligand-gated channels (localized to the plasma membrane) that results in site-specific effects on channel function, in the cases respectively of the large conductance Ca\(^{2+}\)-activated potassium (BK) channels that contain the stress-axis-regulated exon (STREX) splice variant (24–26) and the GluN2A/B subunits of the neuronal N-methyl-D-aspartate glutamate receptor/ion channel (27). However, modification of a single protein by as many as 18 palmitoyl groups is unprecedented.

The direct interaction between RyR1 and Ca\(_V\)1.1 is the principal determinant of RyR1 activation, whereas the interaction of RyR1 with FKB12 (calstabin1) is thought to stabilize the closed conformation of the channel (28). It has recently been reported (29) that FKB12, a cis-trans-prolyl isomerase, binds the small G protein H-Ras, dependent upon H-Ras palmitoylation, and promotes depalmitoylation that is dependent upon a Pro residue proximal to the S-palmitoylated Cys residues within H-Ras (17\(^{199}\)PGCMSC\(^{189}\)). It is of interest that, although Pro residues are not found proximal to S-palmitoylated Cys in the N-terminal cluster of S-palmitoylated Cys that are localized to a predicted FKB1-binding domain within RyR1, Pro residues are found proximal to the two S-palmitoylated Cys that are located adjacent to the predicted C-terminal FKB-binding domain (23\(^{25}\)PCG\(^{232}\) and 23\(^{61}\)PECF\(^{236}\), see Fig. 2). Thus, although speculative, altered palmitoylation of RyRs might play a role in the multiple striated muscle pathophysiology that are reported to be associated with altered FKB12-Ry binding (30).

S-Palmitoylation of various ion channels has been shown to control surface expression, localization to membrane subdomains, internalization and intracellular trafficking, as well as protein–protein interactions (31, 32). These functions have been demonstrated in some cases to reflect the regulation by S-palmitoylation of other post-translational modifications of ion channels, in particular phosphorylation and ubiquitination, which may be exerted through effects of S-palmitoylation on channel subunit configuration (31, 32). However, in addition to possible allosteric regulation, signaling cross-talk between S-palmitoylation and other Cys-based post-translational modification may directly reflect the mutual exclusivity of alternative forms of modification of Cys thiols (33). Our findings indicate substantial overlap between Cys residues identified as sites of S-palmitoylation and those shown previously to be subject to physiological S-oxidation and S-nitrosylation (1, 2, 5). It is possible that a given Cys residue may be preferentially subject to only one modification, but it seems more likely that modification of at least some sites by S-palmitoylation will be antiphasic to modification by S-oxidation or S-nitrosylation, and thus that the state of RyR1 S-palmitoylation will reflect a balance between S-palmitoylation and alternative, redox-based modifications. In addition, to the extent that they occur, interactions between S-palmitoylation and alternative, Cys-based RyR1 modifications might reflect allosteric regulation, as in the case of gating of S-nitrosylation by S-oxidation (1).

Our finding that depalmitoylation of RyR1 substantially suppresses basal channel activity as assessed by \(^{3}\text{H}\)ryanodine binding in both intact SR vesicles and isolated RyR1 suggests that S-palmitoylation of at least some sites within RyR1 influences channel configuration. There are precedents for effects of S-palmitoylation on the gating and activation/inactivation of ion channels, although correlated effects on structural conformation have not been established directly (34–38). Our finding that inhibiting palmitoylation with 2-BP in intact myofibers results in depalmitoylation of at least some Cys residues within RyR1 and also substantially diminishes voltage-triggered Ca\(^{2+}\) release through RyR1 is consistent with the results of chemical depalmitoylation; however, the effects of 2-BP may also reflect depalmitoylation of other proteins that play a role in Ca\(^{2+}\) mobilization through RyR1 (e.g. SERCA 1A and Ca\(_V\)1.1). We conclude that S-palmitoylation is a significant regulator of Ca\(^{2+}\) release from SR stores in skeletal muscle that mediates excitation-contraction coupling and may be expected to play a similar role in RyR-mediated Ca\(^{2+}\) release in the multiple, additional cell types in which one or more forms of RyR operate.

REFERENCES

1. Eu, J. P., Sun, J., Xu, L., Stamler, J. S., and Meissner, G. (2000) The skeletal muscle calcium release channel: coupled O2 sensor and NO signaling functions. Cell 102, 499–509

2. Sun, J., Xin, C., Eu, J. P., Stamler, J. S., and Meissner, G. (2001) Cysteine 3635 is responsible for skeletal muscle ryanodine receptor modulation by NO. Proc. Natl. Acad. Sci. U.S.A. 98, 11158–11162

3. Sun, J., Xu, L., Eu, J. P., Stamler, J. S., and Meissner, G. (2003) Nitric oxide, NOC-12, and S-nitrosoglutathione modulate the skeletal muscle calcium release channel/ryanodine receptor by different mechanisms: an allosteric function for O2 in S-nitrosylation of the channel. J. Biol. Chem. 278, 8184–8189

4. Sun, Q. A., Hess, D. T., Nogueira, L., Yong, S., Bowles, D. E., Eu, J., Laurita, K. R., Meissner, G., and Stamler, J. S. (2011) Oxygen-coupled redox regulation of the skeletal muscle ryanodine receptor-Ca\(^{2+}\) release channel by NADPH oxidase 4. Proc. Natl. Acad. Sci. U.S.A. 108, 16098–16103

5. Sun, Q. A., Wang, B., Miyagi, M., Hess, D. T., and Stamler, J. S. (2013) Oxygen-coupled redox regulation of the skeletal muscle ryanodine receptor-Ca\(^{2+}\)-release channel (RyR1): sites and nature of oxidative modification. J. Biol. Chem. 288, 22961–22971

6. Anderson, K., Cohn, A. H., and Meissner, G. (1994) High-affinity \(^{1}\text{H}\)PN20–110 and \(^{1}\text{H}\)ryanodine binding to rabbit and frog skeletal muscle. Am. J. Physiol. 266, C462–C466

7. Lai, F. A., Erickson, H., Block, B. A., and Meissner, G. (1987) Evidence for a junctional foot-ryanodine receptor complex from sarcoplasmic reticulum. Biochem. Biophys. Res. Commun. 143, 704–709

8. Forrester, M. T., Thompson, J. W., Foster, M. W., Nogueira, L., Moseley,
M. A., and Stamlr, J. S. (2009) Proteomic analysis of S-nitrosylation and deamidation by resin-assisted capture. Nat. Biotechnol. 27, 557–559
9. Forrestor, M. T., Hess, D. T., Thompson, J. W., Hultman, R., Moseley, M. A., Stamlr, J. S., and Casey, P. J. (2011) Site-specific analysis of protein S-acylation by resin-assisted capture. J. Lipid Res. 52, 393–398
10. Eng, J. K., McCormick, A. L., and Yates, J. R. (1994) An approach to correlate tandem mass-spectral data of peptides with amino-acid-sequences in a protein database. J. Am. Soc. Mass. Spectrom. 5, 976–989
11. Xu, T., Venable, J. D., Park, S. K., Cociorva, D., Lu, B., Liao, L., Wohlschlegel, J., Howel, J., and Yates, J. R. (2006) ProLuCID, a fast and sensitive tandem mass-spectra-based protein identification program. Mol. Cell. Proteomics 5, S174
12. Tabb, D. L., McDonald, W. H., and Yates, J. R., 3rd. (2002) DTASelect and Contrast: tools for assembling and comparing protein identifications from shotgun proteomics. J. Proteome Res. 1, 21–26
13. Cociorva, D., Tabb, D., and Yates, J. R. (2007) Validation of tandem mass spectrometry database search results using DTASelect. Curr. Proteom. Bioinform. Chapter 13, Unit 13.4
14. Xu, H., and Fretas, M. A. (2007) A mass accuracy sensitive probability based scoring algorithm for database searching of tandem mass spectrometry data. BMC Bioinformatics 8, 133
15. Lai, F. A., Erickson, H. P., Rousseau, E. L., Qiu, Y., and Meissner, G. (1988) Purification and reconstitution of the calcium release channel from skeletal muscle. Nature 331, 315–319
16. Shefer, G., and Yablonka-Reuveni, Z. (2005) Isolation and culture of skeletal muscle myofibers as a means to analyze satellite cells. Methods Mol. Biol. 290, 281–304
17. Kosower, N. S., and Kosower, E. M. (1987) Thiol labeling with bromobimanes. Methods Enzymol. 143, 76–84
18. Hannoush, R. N., and Arenas-Ramirez, N. (2009) Imaging the lipidome: ω-alkyl fatty acids for detection and cellular visualization of lipid-modified proteins. ACS Chem. Biol. 4, 581–587
19. Martin, B. R., and Cravatt, B. F. (2009) Large-scale profiling of protein palmitoylation in mammalian cells. Nat. Methods 6, 135–138
20. Yap, M. C., Kostiuk, M. A., Martin, D. D., Perimpanayagam, M. A., Hak, P. G., Siddam, A., Majjigapu, J. R., Rajaiah, G., Keller, B. O., Prescher, J. A., Wu, P., Bertozzi, C. R., Falck, J. R., and Berthiaume, L. G. (2010) Rapid and selective detection of fatty acylated proteins using ω-alkyl-fatty acids and click chemistry. J. Lipid Res. 51, 1566–1580
21. Petroetchenko, E. V., Yamauchi, N., Pasek, D. A., Borchers, C. H., and Meissner, G. (2011) Mass spectrometric analysis and mutagenesis predict involvement of multiple cysteines in redox regulation of the skeletal muscle ryanodine receptor ion channel complex. Res. Rep. Biol. 2011, 13–21
22. Olson, E. N., Glaser, L., and Merlie, J. P. (1984) α and β subunits of the nicotinic acetylcholine receptor contain covalently bound lipid. J. Biol. Chem. 259, 5364–5367
23. Dowal, L., Yang, W., Freeman, M. R., Steen, H., and Flammenhaut, R. (2011) Proteomic analysis of palmitoylated platelet proteins. Blood 118, e62–73
24. Tian, L., Jeffries, O., McClafferty, H., MolydysA, A., Rowe, I. C., Saleem, F., Chen, L., Greaves, J., Chamberlain, L. H., Knaus, H. G., Ruth, P., and Shipston, M. J. (2008) Palmitoylation gates phosphorylation-dependent regulation of BK potassium channels. Proc. Natl. Acad. Sci. U.S.A. 105, 21015–21011
25. Jeffries, O., Geiger, N., Rowe, I. C., Tian, L., McClafferty, H., Chen, L., Bi, D., Knaus, H. G., Ruth, P., and Shipston, M. J. (2010) Palmitoylation of the S0-S1 linker regulates cell surface expression of voltage- and calcium-activated potassium (BK) channels. J. Biol. Chem. 285, 33307–33314
26. Zhou, X., Wulfsen, I., Korth, M., McClafferty, H., Lukowski, R., Shipston, M. J., Ruth, P., Dobrev, D., and Wieland, T. (2012) Palmitoylation and membrane association of the stress axis regulated insert (STREX) controls BK channel regulation by protein kinase C. J. Biol. Chem. 287, 32161–32171
27. Hayashi, T., Thomas, G. M., and Huganir, R. L. (2009) Dual palmitoylation of NR2 subunits regulates NMDA receptor trafficking. Neuron 64, 213–226
28. Zalk, R., Lehna, R., and Marks, A. R. (2007) Modulation of the ryanodine receptor and intracellular calcium. Annu. Rev. Biochem. 76, 367–385
29. Ahearn, I. M., Tsai, F. D., Court, H., Zhou, M., Jennings, B. C., Ahmed, M., Fehrenbacher, N., Linder, M. E., and Philips, M. R. (2011) FKBP12 binds to acylated H-ras and promotes depalmitoylation. Mol. Cell. 41, 173–185
30. Betzenhauser, M. J., and Marks, A. R. (2010) Ryanodine receptor channelopathies. Pflugers Arch. 460, 467–480
31. Shipston, M. J. (2011) Ion channel regulation by protein palmitoylation. J. Biol. Chem. 286, 8603–8616
32. Blaskovic, S., Blanc, M., and van der Goot, F. G. (2013) What does S-palmitoylation do to membrane proteins? FEBS J. 280, 2764–2777
33. Hoon, P., Selvakumar, B., Mukai, J., Hester, L. D., Wang, Y., Gogos, J. A., and Snyder, S. H. (2011) S-Nitrosylation and S-palmitoylation reciprocally regulate synaptic targeting of PSD-95. Neuron 71, 131–141
34. Guibotosi-Klug, R. A., Mancuso, D. J., and Gross, R. W. (2005) The human Kv1.1 channel is palmitoylated, modulating voltage sensing: identification of a palmitoylation consensus sequence. Proc. Natl. Acad. Sci. U.S.A. 102, 5964–5968
35. Mueller, G. M., Maarouf, A. B., Kinlough, C. L., Sheng, N., Kashlan, O. B., Okumura, S., Luthy, S., Kleyman, T. R., and Hughey, R. P. (2010) Cys palmitoylation of the β subunit modulates gating of the epithelial sodium channel. J. Biol. Chem. 285, 30453–30462
36. Stephens, G. J., Page, K. M., Bogdanov, Y., and Dolphin, A. C. (2000) The α1A Ca2+ channel amino terminus contributes determinants for β subunit-mediated voltage-dependent inactivation properties. J. Physiol. 525, 377–390
37. Qin, N., Platano, D., Olcese, R., Costantini, J. L., Stefani, E., and Birnbaumer, L. (1998) Unique regulatory properties of the type 2a Ca2+ channel β subunit caused by palmitoylation. Proc. Natl. Acad. Sci. U.S.A. 95, 4690–4695
38. Bosmans, F., Milescu, M., and Swartz, K. J. (2011) Palmitoylation influences the function and pharmacology of sodium channels. Proc. Natl. Acad. Sci. U.S.A. 108, 20213–20218
39. Hwang, J. H., Zorzato, F., Clarke, N. F., and Treves, S. (2012) Mapping domains and mutations on the skeletal muscle ryanodine receptor channel. Trends Mol. Med. 18, 644–657